Combigan may induce allergies

Article

Combigan (brimonidine 0.2%/timolol 0.5%) can cause allergic symptoms in significant numbers of patients, according to Dr Subash and co-workers from Kingston Hospital, UK.

Combigan (brimonidine 0.2%/timolol 0.5%) can cause allergic symptoms in significant numbers of patients, according to Dr Subash and co-workers from Kingston Hospital, UK.

Thirty-two patients who began Combigan therapy between April 2005 and February 2006 were enrolled to an open-label, prospective, six-month surveillance study. All patients were sent a patient satisfaction questionnaire.

After a mean follow-up of 23.1 weeks, a mean reduction in IOP of 5.5 mmHg was achieved. Greatest IOP lowering was seen in patients who switched from timolol alone and from dorzolamide/timolol combinations. Side effects that resulted in discontinuation of Combigan were tachypnoea (9.4%) and allergic conjunctivitis (34.4%). Patients who did not develop adverse side effects were satisfied with Combigan.

Dr Subash concluded that, although Combigan offers good IOP lowering and is generally safe, a substantial number of patients taking the therapy will develop allergic symptoms.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.